Bioequivalence indicates that a generic allopurinol product delivers the same rate and extent of absorption as the reference formulation, ensuring comparable plasma concentrations under identical conditions.
Manufacturing scale and supply diversity allow several WHO-GMP-certified facilities to produce the compound, reducing reliance on a single source and facilitating broader distribution.
Having several producers creates redundancy, mitigates potential disruptions, and enables the logistics platform to source from the most readily available inventory.
Tablet colour, shape, and imprint may differ across manufacturers or production runs, though each batch conforms to the same pharmacopoeial specifications.
Keeping tablets at 20 °C-25 °C, away from moisture and direct light, maintains chemical integrity throughout the labelled shelf life.
Travelers may bring a limited supply for personal use, subject to HSA-defined quantity thresholds; always verify the current limits directly with the HSA as regulations may change.
Allopurinol is not typically included in routine workplace drug-testing panels; detection methods focus on substances with abuse potential, though specialized testing can identify its metabolites if required.
Patients experiencing gout-related discomfort often require a medication that limits uric acid production. Allopurinol - available as a 300 mg oral pill - provides the standard concentration used in chronic management. The tablet form is manufactured in multiple strengths, but 300 mg remains the common prescription dose for routine therapy.
Allopurinol exerts its effect by inhibiting xanthine oxidase (the enzyme that converts hypoxanthine and xanthine into uric acid). This blockade reduces the formation of uric acid, thereby lowering serum concentrations that can precipitate gout crystals. The drug is metabolised to oxypurinol, which continues to inhibit the same enzyme throughout its longer half-life.
The active ingredient allopurinol is recognised by Singapore’s Health Sciences Authority (HSA) as a therapeutic agent indicated for the long-term management of hyperuricaemia associated with gout. It serves as a standard intervention for reducing uric acid levels in patients with recurrent gout attacks.
Individuals with a documented allergy to allopurinol should avoid use and seek professional guidance.
Patients with markedly reduced kidney function are at heightened risk of accumulation and should be evaluated by a physician before any exposure.
All dosing, frequency, duration, and escalation decisions are determined exclusively by a supervising physician.
Allopurinol tablets are taken orally and should be swallowed whole with an adequate amount of water. The medication can be administered with or without meals, and all decisions regarding dosing schedules rest with the patient’s physician.
Store the tablets at controlled room temperature, ideally between 20 °C and 25 °C, protected from excessive moisture and direct sunlight. Shelf-life information is provided on the packaging; expired or unused tablets must be disposed of in accordance with Singapore’s local pharmaceutical waste regulations.
The generic formulation of allopurinol is sourced from manufacturers such as Teva, Cipla, and Sun Pharma, with the platform acting solely as an international logistics intermediary. All products are supplied through WHO-GMP compliant channels, and verified manufacturers are listed for transparency. Confirmed orders are redirected to an external third-party payment processor.
The information presented herein is for educational purposes only and does not constitute medical advice. This platform functions exclusively as a brokerage intermediary and does not operate as a pharmacy. No clinical recommendations are offered; readers should consult a qualified physician and review the accompanying product insert. Importation of allopurinol into Singapore must comply with HSA regulations, and users bear full responsibility for adhering to those legal requirements.
